Beruflich Dokumente
Kultur Dokumente
METABOLISM OR BIOTRANSFORMATION
The conversion from one chemical form of a substance to another.
The term metabolism is commonly used probably because products of drug
transformation are called metabolites.
Functions of Biotransformation
It causes conversion of an
active drug to inactive or
less active metabolite(s)
called as pharmacological
inactivation.
It causes conversion of an
active to more active
metabolite(s) called as
bioactivation
or
toxicological activation.
It causes conversion of an
inactive to more active
toxic metabolite(s) called
as lethal synthesis
Functions of Biotransformation.contd
It causes conversion of an
inactive drug (pro-drug) to
active metabolite(s) called
as
pharmacological
activation
It causes conversion of an
active drug to equally active
metabolite(s) (no change in
pharmacological activity)
It causes conversion of an
active drug to active
metabolite(s)
having
entirely
different
pharmacological
activity
(change in pharmacological
activity)
Sites of Biotransformationcontd
Liver
The primary site for metabolism of almost all drugs because it is relatively
rich in a large variety of metabolising enzymes.
Metabolism by organs other than liver (called as extra-hepatic metabolism)
is of lesser importance because lower level of metabolising enzymes is
present in such tissues.
Within a given cell, most drug metabolising activity is found in the smooth
endoplasmic reticulum and the cytosol.
Drug metabolism can also occur in mitochondria, nuclear envelope and
plasma membrane.
A few drugs are also metabolised by non-enzymatic means called as nonenzymatic metabolism.
For example, atracurium, a neuromuscular blocking drug, is inactivated in
plasma by spontaneous non-enzymatic degradation (Hoffman elimination)
in addition to that by pseudocholinesterase enzyme.
Subcellular
Locations
of
Metabolizing
Enzymes
transferase,
etc
are
Non-microsomal
enzymes:
Enzymes
occurring
in
organelles/sites
other
than
endoplasmic
reticulum
(microsomes) are called non-microsomal enzymes.
These are usually present in the cytoplasm, mitochondria, etc.
and occur mainly in the liver, Gl tract, plasma and other tissues.
They are usually non-specific enzymes that catalyse few
oxidative reactions, a number of reductive and hydrolytic
reactions, and all conjugative reactions other than
glucuronidation.
None of the non-microsomal enzymes involved in drug
biotransformation is known to be inducible.
Drug Metabolism
TYPES OF BIOTRANSFORMATION
Phase 1 reaction. (Non synthetic phase).
a change in drug molecule. generally
results in the introduction of a
functional group into molecules or the
exposure of new functional groups of
molecules
: Phase I (non-synthetic or nonconjugative phase) includes reactions
which catalyse oxidation, reduction and
hydrolysis of drugs.
In phase I reactions, small polar
functional groups like-OH, -NH2. -SH, COOH, etc. are either added or
unmasked (if already present) on the
lipid soluble drugs so that the resulting
products may undergo phase II
reactions.
result in activation, change or
inactivation of drug.
Enzymes:
PHASE I BIOTRANSFORMATION
Oxidation
mixed-
Phase I Reactions
Oxidation :
Oxidative reactions are most important metabolic reactions, as
energy in animals is derived by oxidative combustion of organic
molecules containing carbon and hydrogen atoms.
The oxidative reactions are important for drugs because they
increase hydrophilicity of drugs by introducing polar functional
groups such as -OH.
Oxidation of drugs is non-specifically catalysed by a number of
enzymes located primarily in the microsomes. Some of the
oxidation reactions are also catalysed by non-microsomal enzymes
(e.g., aldehyde dehydrogenase, xanthine oxidase and monoamine
oxidase).
PHASE I ENZYMES
Cytochrome P450
Monooxygenase
(Cytochrome P450, P450,
or CYP)
Flavin-Containing
Monooxygenase (FMO)
Esterase
Alcohol Dehydrogenase
(ADH)
Aldehyde
Dehydrogenase (ALDH)
Monoamine
Oxidase
(MAO)
PHASE II ENZYMES
Uridine
DiphosphateGlucuronosyltransferase
(UDPGT)
Sulfotransferase (ST)
N-Acetyltransferase (NAT)
Glutathione
S-Transferase
(GST)
Methyl Transferase
Amino Acid Conjugation
% DRUGS METABOLIZED
BY CYP ENZYMES
CYP2E1
7%
CYP 2C19
11%
CYP 2C9
14%
CYP 2C
17%
OTHER
36%
CYP 1A2
12%
CYP 3A4-5
26%
CYP2D6
23%
CYP 1A2
14%
CYP 3A4-5
33%
CYP2E1
5%
1A2
2A6
17-Estradiol, Testosterone
2B6
2C-family
2E1
2D6
3A4
2. Reduction :
Reduction
Enzymes responsible for reduction of xenobiotics require NADPH as a cofactor.
Substrates for reductive reactions include azo- or nitrocompounds, epoxides,
heterocyclic compounds, and halogenated hydrocarbons:
(a) Azo or nitroreduction by cytochrome P450;
(b) Carbonyl (aldehyde or ketone) reduction by aldehyde reductase, aldose
3. Hydrolysis :
Esters, amides, hydrazides, and carbamates can be hydrolyzed by
various
enzymes.
The hydrolytic reactions, contrary to oxidative or reductive
reactions, do not involve change in the state of oxidation of the
substrate, but involve the cleavage of drug molecule by taking up
a molecule of water.
The hydrolytic enzymes that metabolise drugs are the ones that
act on endogenous substances, and their activity is not confined
to liver as they are found in many other organs like kidneys,
intestine, plasma, etc.
A number of drugs with ester, ether, amide and hydrazide
linkages undergo hydrolysis. Important examples are
cholinesters, procaine, procainamide, and pethidine.
PHASE II REACTIONS
Phase II or conjugation (Latin, conjugatus = yoked together)
reactions involve combination of the drug or its phase I
metabolite with an endogenous substance to form a highly polar
product, which can be efficiently excreted from the body.
In the biotransformation of drugs, such products or metabolites
have two parts:
Exocon, the portion derived from exogenous compound or
xenobiotic,
Endocon, the portion derived from endogenous substance.
Conjugation reactions have high energy requirement and they
often utilise suitable enzymes for the reactions.
INDUCTION OF METABOLISM
Administration of certain xenobiotics sometimes results in a
selective increase in the concentration of metabolizing enzymes in
both phase I and II metabolism, and thereby in their activities
Enzyme induction becomes important especially when
polypharmacy involves drugs with narrow therapeutic windows, since
the induced drug metabolism could result in a significant decrease in
its exposure and therapeutic effects.
In addition, enzyme induction may cause toxicity, associated with
increased production of toxic metabolites.
Mechanisms of Induction
Stimulation of transcription of genes and/or translation of proteins,
and/or stabilization of mRNA and/or enzymes by inducers, resulting in
elevated enzyme levels.
Characteristics of Induction
Induction is a function of intact cells and cannot be achieved by treating
isolated cell fractions such as microsomes with inducers.
Evaluation of enzyme induction is usually conducted in ex vivo experiments,
ie., treating animals in vivo with potential inducers and measuring enzyme
activities in vitro or in cell-based in vitro preparations such as hepatocytes, liver
slices, or cell lines.
Recent studies have demonstrated that primary cultures of hepatocytes can
be used for studying the inducibility of metabolizing enzymes such as P450 under
certain incubation conditions
Enzyme induction is usually inducer-concentrationdependent. The extent of
induction increases as the inducer concentration increases; however, above
certain values, induction starts to decline.
In general, inducers increase the content of endoplasmic reticulum within
hepatocytes as well as liver weight.
In some cases, an inducer induces enzymes responsible for its own
metabolism (so-called autoinduction).
Inducing Agents
EXTRAHEPATIC METABOLISM
This may occur during passage of drug for first time (therefore called first-pass
effect/metabolism) through intestine or liver after oral administration.
Intestinal first-pass effect: In this type, drugs are metabolised in the gastrointestinal
tract by enzymes present in either gut mucosa or gut lumen before they are
absorbed
Recent studies have indicated that P450 isoforms such as CYP2C19 and 3A4 in
enterocytes might play an important role in the presystemic intestinal metabolism of
drugs and the large interindividual variability in systemic exposure after oral
administration
The cytochrome P450 content of the intestine is about 35% of the hepatic content
in the rabbit, but accounts for only 4% of the hepatic content in the mouse.
Cytochrome P450 levels and activities are highest in the duodenum near the
pyrolus, and then decrease toward the colon
A similar trend in regional activity levels along the intestine has been observed for
glucuronide, sulfate, and glutathione conjugating enzymes.
Renal Metabolism
In addition to physiological functions of homeostasis in water and
electrolytes and the excretion of endogenous and exogenous compounds
from the body, the kidneys are the site of significant biotransformation
activities for both phase I and phase II metabolism.
The renal cortex, outer medulla, and inner medulla exhibit different
profiles of drug metabolism, which appears to be due to heterogeneous
distribution of metabolizing enzymes along the nephron.
Most metabolizing enzymes are localized mainly in the proximal tubules,
although various enzymes are distributed in all segments of the nephron
The pattern of renal blood flow, pH of the urine, and the urinary
concentrating mechanism can provide an environment that facilitates the
precipitation of certain compounds, including metabolites formed within the
kidneys.
The high concentration or crystallization of xenobiotics and/or their
metabolites can potentially cause significant renal impairment in specific
regions of the kidneys.
Metabolism in Blood
Blood contains various proteins and enzymes.
As metabolizing enzymes, esterases, including cholinesterase,
arylesterase, and carboxylesterase, have the most significant effects
on hydrolysis of compounds with ester, carbamate, or phosphate
bonds in blood .
Esterase activity can be found mainly in plasma, with less activity in
red blood cells.
Plasma albumin itself may also act as an esterase under certain
conditions.
For instance, albumin contributes about 20% of the total hydrolysis
of aspirin to salicylic acid in human plasma.
The esterase activity in blood seems to be more extensive in small
animals such as rats than in large animals and humans. Limited, yet
significant monoamine oxidase activities can be also found in blood.
THANK YOU